Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

msh id	COM:RECURSION
symbol	RXRX
name	Recursion Pharmaceuticals, Inc.
homepage url	https://www.recursion.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	500
crunchbase url	-
linkedin url	-
founders	-

market cap	1.89B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.38
growth cost of revenue	0.06
growth depreciation and amortization	1.76
growth ebitda	-0.29
growth ebitda ratio	-0.15
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.36
growth gross profit	0.24
growth gross profit ratio	0.33

COM:RECURSION

Recursion

Last Close

6.04

21/11 19:40

Market Cap

1.89B

Beta: -

Volume Today

9.73M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	394.64M
cost of revenue	394.64M
depreciation and amortization	32.47M
ebitda	-317.6M
ebitda ratio	-7.12
eps	-1.58
eps diluted	-1.58
operating expenses	343.55M
operating income	-350.06M
operating income ratio	-7.85

accounts receivables	-7.76M
capital expenditure	-12.55M
cash at beginning of period	551.19M
cash at end of period	394.8M
inventory	-3.09M
working capital ttm	316.4M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-